These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 9099774)

  • 1. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease.
    Wang EE; Law BJ; Robinson JL; Dobson S; al Jumaah S; Stephens D; Boucher FD; McDonald J; Mitchell I; MacDonald NE
    Pediatrics; 1997 Mar; 99(3):E9. PubMed ID: 9099774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.
    Wang EE; Law BJ; Stephens D
    J Pediatr; 1995 Feb; 126(2):212-9. PubMed ID: 7844667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database.
    Law BJ; Wang EE; MacDonald N; McDonald J; Dobson S; Boucher F; Langley J; Robinson J; Mitchell I; Stephens D
    Pediatrics; 1997 Mar; 99(3):E7. PubMed ID: 9099772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
    Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada.
    Navas L; Wang E; de Carvalho V; Robinson J
    J Pediatr; 1992 Sep; 121(3):348-54. PubMed ID: 1517907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.
    Wang EE; Law BJ; Boucher FD; Stephens D; Robinson JL; Dobson S; Langley JM; McDonald J; MacDonald NE; Mitchell I
    J Pediatr; 1996 Sep; 129(3):390-5. PubMed ID: 8804328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of respiratory syncytial virus infection as a cause of lower respiratory tract infection in children younger than 3 years of age in Japan.
    Kaneko M; Watanabe J; Kuwahara M; Ueno E; Hida M; Kinoshita A; Sone T
    J Infect; 2002 May; 44(4):240-3. PubMed ID: 12099731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of respiratory syncytial virus immune globulin in 1996-1997: a local controlled comparison.
    Redding GJ; Braun S; Mayock D
    Arch Pediatr Adolesc Med; 1999 May; 153(5):503-7. PubMed ID: 10323631
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.
    Piedra PA; Jewell AM; Cron SG; Atmar RL; Glezen WP
    Vaccine; 2003 Jul; 21(24):3479-82. PubMed ID: 12850364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.
    Simoes EA; Sondheimer HM; Top FH; Meissner HC; Welliver RC; Kramer AA; Groothuis JR
    J Pediatr; 1998 Oct; 133(4):492-9. PubMed ID: 9787686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
    Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
    Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.
    Eick A; Karron R; Shaw J; Thumar B; Reid R; Santosham M; O'Brien KL
    Pediatr Infect Dis J; 2008 Mar; 27(3):207-12. PubMed ID: 18277934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus infection in elderly and high-risk adults.
    Falsey AR; Hennessey PA; Formica MA; Cox C; Walsh EE
    N Engl J Med; 2005 Apr; 352(17):1749-59. PubMed ID: 15858184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for severe respiratory syncytial virus-associated lower respiratory tract infection in children.
    Kaneko M; Watanabe J; Ueno E; Hida M; Sone T
    Pediatr Int; 2001 Oct; 43(5):489-92. PubMed ID: 11737710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody response to respiratory syncytial virus infection in children <18 months old.
    Esposito S; Scarselli E; Lelii M; Scala A; Vitelli A; Capone S; Fornili M; Biganzoli E; Orenti A; Nicosia A; Cortese R; Principi N
    Hum Vaccin Immunother; 2016 Jul; 12(7):1700-6. PubMed ID: 26901128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response and avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children.
    Freitas GR; Silva DA; Yokosawa J; Paula NT; Costa LF; Carneiro BM; Ribeiro LZ; Oliveira TF; Mineo JR; Queiróz DA
    J Med Virol; 2011 Oct; 83(10):1826-33. PubMed ID: 21837801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.